Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a ...
Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...
Leveraging advanced spatial proteomics, scientists have identified the JAK/STAT pathway as a critical target for treating toxic epidermal necrolysis, offering new hope for patients with this ...
VEXAS is a UBA1-driven, male-predominant clonal myeloid disorder combining systemic inflammation with macrocytic anemia, thrombocytopenia, marrow failure, and 30–40% five-year mortality without ...
JAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for treating various diseases, including autoimmune disorders and cancers. JAK (Janus Kinase) inhibitors, ...
A new Janus kinase inhibitor medication, deuruxolitinib (Leqselvi, Sun Pharma UK Limited), has been approved in the UK for the treatment of severe alopecia areata in adult patients. The Medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results